3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
3
Melanoma
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Incontinence
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Esophageal Neoplasms
1
Erectile Dysfunction
1
Desmoid Tumors
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
12
Radiotherapy
9
avelumab
8
Nivolumab
8
cemiplimab
4
Radiation
4
Ipilimumab
4
poly ICLC
3
atezolizumab
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Etoposide
3
Cyclophosphamide
3
talimogene laherparepvec
2
lutetium Lu 177 dotatate
2
fludarabine phosphate
2
fludarabine
2
durvalumab
2
aldesleukin
2
Interferon-beta
2
Immunoglobulin G
2
Immune Checkpoint Inhibitors
2
Cisplatin
2
Carboplatin
2
Biopsy
2
veliparib
1
vatalanib
1
tremelimumab
1
tocilizumab
1
temsirolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Merkel Cell
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled